著者

Takashi Kurita Keiko Ishida Emiri Muranaka Hiroki Sasazawa Haruki Mito Yudai Yano Ryota Hase

出版者

The Japanese Society of Internal Medicine

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

vol.59, no.22, pp.2951-2953, 2020-11-15 (Released:2020-11-15)

参考文献数

14

被引用文献数

7

---

We herein report the first case of a fever induced by favipiravir, a potential coronavirus disease 2019 therapeutic drug. An 82-year-old man diagnosed with bilateral pneumonia was transferred to our hospital following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test. He was treated with compassionate use of favipiravir. Both his oxygen demand and fever gradually improved after admission; however, his fever relapsed, and the C-reactive protein (CRP) levels increased on day 7. We diagnosed his fever as being favipiravir-induced. The fever resolved a few days after favipiravir discontinuation, demonstrating the accuracy of the diagnosis. This case revealed that favipiravir can induce a fever.

著者

Ryota Hase Rika Kurata Keiko Ishida Takashi Kurita Emiri Muranaka Haruki Mito

出版者

The Japanese Society of Internal Medicine

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

pp.5377-20, (Released:2020-07-28)

参考文献数

10

被引用文献数

12

---

A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.

著者

Yusuke Ainoda Nozomi Takeshita Ryota Hase Takahiro Mikawa Naoto Hosokawa Ichiro Kawamura Hanako Kurai Masahiro Abe Muneyoshi Kimura Hideki Araoka Takahiro Fujita Kyoichi Totsuka Kazuhisa Mezaki Noritaka Sekiya Norio Ohmagari

出版者

国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会

雑誌

Japanese Journal of Infectious Diseases (ISSN:13446304)

巻号頁・発行日

pp.JJID.2016.130, (Released:2016-12-22)

参考文献数

17

被引用文献数

7

---

Staphylococcus lugdunensis (SL) is a highly pathogenic bacterium compared to other coagulase-negative Staphylococcus spp. (CoNS). However, in Japan, data for this pathogen are sparse, and the current prevalence of SL bacteremia is unknown.A prospective multicenter study across five facilities was performed to investigate the prevalence of SL in blood culture specimens. There were 3,284 patients with positive blood cultures, and 2,478 patients had bacteremia. Among patients with bacteremia, 7 patients (0.28%) had SL bacteremia. A total of 281 patients had CoNS bacteremia, and SL accounted for 2.49% of these cases. Of the 7 patients with SL bacteremia, 1 patient (14.3%) had infective endocarditis, and 1 patient (14.3%) died within 30 days. In this study, SL resulted in the development of bacteremia in select patients. Clinicians in Japan should be aware of the prevalence of SL and the complications of SL bacteremia.

著者

Yusuke Ainoda Nozomi Takeshita Ryota Hase Takahiro Mikawa Naoto Hosokawa Ichiro Kawamura Hanako Kurai Masahiro Abe Muneyoshi Kimura Hideki Araoka Takahiro Fujita Kyoichi Totsuka Kazuhisa Mezaki Noritaka Sekiya Norio Ohmagari

出版者

National Institute of Infectious Diseases

雑誌

Japanese Journal of Infectious Diseases (ISSN:13446304)

巻号頁・発行日

vol.70, no.4, pp.405-407, 2017 (Released:2017-07-24)

参考文献数

17

被引用文献数

7 7

---

Staphylococcus lugdunensis (SL) is a bacterium with a highly pathogenicity than most other coagulase-negative Staphylococcus spp. (CoNS). In Japan, data on this pathogen are sparse, and the current prevalence of SL bacteremia is unknown. Therefore, we investigated the prevalence of SL in blood culture specimens in a prospective multicenter study across 5 facilities. A total of 3,284 patients had positive blood cultures, and 2,478 patients had bacteremia. Among the patients with bacteremia, 7 patients (0.28%) had SL bacteremia. A total of 281 patients had CoNS bacteremia, with SL accounting for 2.49% of these cases. Of the 7 patients with SL bacteremia, 1 patient (14.3%) had infective endocarditis, and 1 patient (14.3%) died within 30 days. In this study, SL resulted in the development of bacteremia in select patients. Clinicians in Japan should be aware of the prevalence of SL and the complications of SL bacteremia.